Table 3 |
||||||||
|
Number of EGFR, HER2, pPI3K, and pAkt-positive CTCs in breast cancer patients |
||||||||
| Number of CTCs per sample |
EGFR |
HER2 |
pPI3K |
PAkt |
||||
|
|
||||||||
| Early disease (n = 16) |
Metastatic disease (n = 16) |
Early disease (n = 16) |
Metastatic disease (n = 16) |
Early disease (n = 16) |
Metastatic disease (n = 16) |
Early disease (n = 16) |
Metastatic disease (n = 16) |
|
|
|
||||||||
| 1 |
2 (13) |
1 (6) |
5 (31) |
6 (38) |
6 (31) |
3 (19) |
5 (31) |
4 (25) |
|
|
||||||||
| 2 |
4 (25) |
1 (6) |
1 (6) |
2 (13) |
5 (31) |
2 (13) |
4 (25) |
3 (19) |
|
|
||||||||
| 3 |
- |
- |
- |
- |
- |
4 (25) |
1 (6) |
2 (13) |
|
|
||||||||
| 4 |
- |
2 (13) |
1 (6) |
1 (6) |
2 (13) |
2 (13) |
- |
|
|
|
||||||||
| ≥ 5 |
- |
3 (19) |
1 (6) |
1 (6) |
1 (6) |
5 (31) |
1 (6) |
4 (25) |
|
|
||||||||
|
Values are expressed as number (%). CTC, circulating tumor cell; EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; PI3K, phosphoinositide-3 kinase. |
||||||||
|
Kallergi et al. Breast Cancer Research 2008 10:R80 doi:10.1186/bcr2149 |
||||||||
